Compare Matson Inc (MATX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Repligen Corporation Common Stock — how do they compare? Matson Inc trades at $235.22 (market cap $7.04B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Matson Inc pays a 0.65% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 25 Days and Repligen Corporation Common Stock for 0 Days on average.
| MATX | RGEN | |
|---|---|---|
Market Cap | $7.04B | $11.31B |
Volume | 295,660 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $238.60 | $194.57 |
52-Week Low | $93.22 | $102.87 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $7.64B | $11.20B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $235.22, up 3.31% with strong bullish momentum supported by consistent earnings beats and positive technical indicators. The stock shows robust fundamentals with a 13.41% net income margin and 17.21% ROE, while valuation metrics remain reasonable with a P/E of 15.87. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 expected, driving positive sentiment.
Outlook remains positive with Wall Street analysts projecting 27.3% upside potential and strong institutional buying activity. Key risks include freight market volatility and competitive pressures, but the company's raised full-year guidance and dividend payments provide stability for investors seeking transportation sector exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
